Patricia K. Donahoe

Patricia K. Donahoe's AcademicInfluence.com Rankings

Patricia K. Donahoe

Medical

#1640

World Rank

#2002

Historical Rank

#410

USA Rank

Pediatrics

#47

World Rank

#57

Historical Rank

#15

USA Rank

medical Degrees

Download Badge

Medical

Patricia K. Donahoe's Degrees

Doctorate Medicine Harvard University

Why Is Patricia K. Donahoe Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Patricia Kilroy Donahoe is an American pediatric surgeon and a leading researcher in the field of developmental biology and oncology. She was the president of the American Pediatric Surgical Association from 2006 to 2007. She currently serves as the director of pediatric surgical research laboratories and chief emerita of pediatric surgical services at Massachusetts General Hospital.

(See a Problem?)

Patricia K. Donahoe's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Detection of large-scale variation in the human genome (2004) (2971)
Isolation of the bovine and human genes for müllerian inhibiting substance and expression of the human gene in animal cells (1986) (1009)
Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. (2000) (878)
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. (2006) (769)
Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. (1996) (425)
Comprehensive assessment of array-based platforms and calling algorithms for detection of copy number variants (2011) (405)
The Immunophilin FKBP12 Functions as a Common Inhibitor of the TGFβ Family Type I Receptors (1996) (368)
Mullerian inhibiting substance: a gonadal hormone with multiple functions. (1993) (347)
Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12. (1994) (340)
Müllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. (2001) (317)
A transforming growth factor beta type I receptor that signals to activate gene expression. (1994) (298)
Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes (2007) (295)
A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes (2008) (285)
Sex determination and differentiation. (2004) (275)
The type I serine/threonine kinase receptor ActRIA (ALK2) is required for gastrulation of the mouse embryo. (1999) (261)
Molecular basis of mammalian sexual determination: activation of Müllerian inhibiting substance gene expression by SRY. (1994) (256)
An immunoassay to detect human müllerian inhibiting substance in males and females during normal development. (1990) (245)
The type I activin receptor ActRIB is required for egg cylinder organization and gastrulation in the mouse. (1998) (235)
Proteolytic processing of mullerian inhibiting substance produces a transforming growth factor-beta-like fragment. (1988) (196)
Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. (2005) (190)
The epithelial-mesenchymal interface of the male rate Mullerian duct: loss of basement membrane integrity and ductal regression. (1982) (182)
Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. (2001) (171)
Mullerian inhibiting substance messenger ribonucleic acid expression in granulosa and Sertoli cells coincides with their mitotic activity. (1992) (170)
Measurements of serum müllerian inhibiting substance in the evaluation of children with nonpalpable gonads. (1997) (170)
Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor‐β type II receptor family (1993) (160)
Endogenous expression of Müllerian inhibiting substance in early postnatal rat sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites. (2000) (159)
HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis (2009) (153)
Dysgenesis of testicular and streak gonads in the syndrome of mixed gonadal dysgenesis: perspective derived from a clinicopathologic analysis of twenty-one cases. (1982) (147)
SRY recognizes conserved DNA sites in sex-specific promoters. (1993) (146)
Mullerian inhibiting substance in the adult rat ovary during various stages of the estrous cycle. (1989) (145)
Congenital diaphragmatic hernia and chromosome 15q26: determination of a candidate region by use of fluorescent in situ hybridization and array-based comparative genomic hybridization. (2005) (138)
AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy (2017) (134)
Developmental expression of a candidate müllerian inhibiting substance type II receptor. (1996) (134)
Müllerian inhibiting substance as a marker for ovarian sex-cord tumor. (1992) (133)
Müllerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFκB-mediated Pathway* (2000) (132)
A graded organ culture assay for the detection of Mullerian inhibiting substance. (1977) (131)
Müllerian inhibiting substance as oocyte meiosis inhibitor (1986) (130)
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. (1999) (130)
The ontogeny of mullerian inhibiting substance in granulosa cells of the bovine ovarian follicle. (1986) (127)
Requirement for phosphatidylinositol-3'-kinase in cytokine-mediated germ cell survival during fetal oogenesis in the mouse. (1999) (126)
Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics (2008) (125)
Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance (2012) (123)
Cellular localization of müllerian inhibiting substance in the developing rat ovary. (1989) (122)
Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development (2012) (120)
Biochemical immaturity of lungs in congenital diaphragmatic hernia. (1993) (117)
The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells. (1992) (112)
Effect of dry and humidified gases on the respiratory epithelium in rabbits. (1975) (110)
Antenatal Glucocorticoid Corrects Pulmonary Immaturity in Experimentally Induced Congenital Diaphragmatic Hernia in Rats (1994) (110)
The ontogeny of Mullerian inhibiting substance in the gonads of the chicken. (1981) (105)
The p21RAS Farnesyltransferase α Subunit in TGF-β and Activin Signaling (1996) (104)
Müllerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics (2010) (102)
Mixed gonadal dysgenesis, pathogensis, and management. (1979) (102)
Infants with Bochdalek diaphragmatic hernia: Sibling precurrence and monozygotic twin discordance in a hospital‐based malformation surveillance program (2005) (96)
Mullerian-Inhibiting Substance (1990) (96)
Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro. (1988) (94)
Müllerian Inhibiting Substance Inhibits Ovarian Cell Growth through an Rb-independent Mechanism* (2000) (93)
Mullerian inhibiting substance in human testes after birth. (1977) (93)
Mullerian inhibiting substance acts as a motor neuron survival factor in vitro. (2005) (93)
Dissecting spatio-temporal protein networks driving human heart development and related disorders (2010) (92)
Adult Mouse Myometrial Label‐Retaining Cells Divide in Response to Gonadotropin Stimulation (2007) (91)
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance. (2005) (90)
Prenatal glucocorticoid therapy reverses pulmonary immaturity in congenital diaphragmatic hernia in fetal sheep. (1996) (89)
Regulation of sexual dimorphism in mammals. (1998) (87)
Müllerian inhibiting substance activity in bovine fetal, newborn and prepubertal testes. (1977) (87)
Programmed cell death in the Müllerian duct induced by Müllerian inhibiting substance. (1977) (85)
Correction of congenital abnormalities of the vagina and perineum. (1980) (83)
MIS/AMH in the assessment of cryptorchidism and intersex conditions (2003) (82)
Diagnostic utility of Müllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. (1999) (82)
Müllerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer. (1979) (81)
Mullerian inhibiting substance ontogeny and its modulation by follicle-stimulating hormone in the rat testes. (1990) (81)
Mullerian inhibiting substance fractionation by dye affinity chromatography (1983) (77)
Estrogen inhibition of Mullerian inhibiting substance in the chick embryo. (1982) (77)
Findings from aCGH in patients with congenital diaphragmatic hernia (CDH): A possible locus for Fryns syndrome (2006) (77)
Congenital diaphragmatic hernia candidate genes derived from embryonic transcriptomes (2012) (76)
Gonadotropin-releasing hormone agonist-induced differences in granulosa cell cycle kinetics are associated with alterations in follicular fluid müllerian-inhibiting substance and androgen content. (1993) (76)
Surgical treatment of congenital adrenal hyperplasia. (2001) (75)
Müllerian-inhibiting substance: an update. (1982) (74)
MEK-1/2 inhibition reduces branching morphogenesis and causes mesenchymal cell apoptosis in fetal rat lungs. (2002) (74)
Müllerian inhibiting substance inhibits testosterone synthesis in adult rats. (2001) (73)
Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression (2006) (73)
Müllerian inhibiting substance gene expression in the cycling rat ovary correlates with recruited or graafian follicle selection. (1994) (73)
The immunophilin FKBP12: a molecular guardian of the TGF-beta family type I receptors. (2004) (72)
Preputial unfurling to correct the buried penis. (1986) (72)
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107 (2003) (71)
Müllerian Inhibiting Substance Regulates NFκB Signaling and Growth of Mammary Epithelial Cells in Vivo* (2001) (71)
De novo variants in congenital diaphragmatic hernia identify MYRF as a new syndrome and reveal genetic overlaps with other developmental disorders (2018) (70)
Müllerian-Inhibiting Substance Type II Receptor Expression and Function in Purified Rat Leydig Cells. (1999) (70)
Measurement of Mullerian inhibiting substance facilitates management of boys with microphallus and cryptorchidism. (2002) (70)
Pneumoperitoneum secondary to pulmonary air leak. (1972) (70)
Uterine Leiomyomas Exhibit Fewer Stem/Progenitor Cell Characteristics When Compared With Corresponding Normal Myometrium (2010) (69)
Human müllerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects. (1992) (69)
Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line. (1982) (68)
The production of Mullerian inhibiting substance by the fetal, neonatal and adult rat. (1976) (68)
Müllerian-Inhibiting Substance Regulates Androgen Synthesis at the Transcriptional Level1. (1999) (68)
Specific estradiol binding in embryonic Mullerian ducts: a potential modulator of regression in the male and female chick. (1983) (68)
Sex-specific fetal lung development and müllerian inhibiting substance. (1990) (68)
Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo. (2002) (67)
Prenatal hormonal therapy improves pulmonary compliance in the nitrofen-induced CDH rat model. (1995) (67)
Laryngotracheoesophageal cleft (type IV): management and repair of lesions beyond the carina. (1991) (66)
Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo. (1991) (65)
Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain. (1992) (64)
Müllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents (2001) (64)
New insights into mullerian inhibiting substance and its mechanism of action. (1998) (63)
Mullerian-inhibiting substance regulates NF–κB signaling in the prostate in vitro and in vivo (2002) (63)
Isolation of the rat gene for Mullerian inhibiting substance. (1992) (62)
Feedback inhibition of steroidogenic acute regulatory protein expression in vitro and in vivo by androgens. (2004) (60)
Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat. (1992) (60)
Müllerian inhibiting substance production associated with loss of oocytes and testicular differentiation in the transplanted mouse XX gonadal primordium. (1993) (60)
Müllerian inhibiting substance: gene structure and mechanism of action of a fetal regressor. (1987) (59)
Müllerian inhibiting substance blocks autophosphorylation of the EGF receptor by inhibiting tyrosine kinase (1987) (59)
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay. (1985) (59)
Müllerian inhibiting substance is present in embryonic testes of dogs with persistent müllerian duct syndrome. (1989) (59)
Congenital diaphragmatic hernia--does the side of the defect influence the incidence of associated malformations? (1998) (58)
Müllerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome p450 17alpha-hydroxylase/C(17-20) lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation. (2002) (58)
Steroid modulation of Mullerian duct regression in the chick embryo. (1985) (57)
Congenital diaphragmatic hernia (CDH) etiology as revealed by pathway genetics (2007) (57)
Donnai–Barrow syndrome (DBS/FOAR) in a child with a homozygous LRP2 mutation due to complete chromosome 2 paternal isodisomy (2008) (56)
Phosphorylation events during Müllerian duct regression. (1984) (55)
Chick pulmonary Wnt5a directs airway and vascular tubulogenesis (2008) (54)
Management and long-term follow-up of patients with types III and IV laryngotracheoesophageal clefts. (2005) (54)
Characterization of the chromosome 1q41q42.12 region, and the candidate gene DISP1, in patients with CDH (2010) (54)
Observations on the gubernaculum during descent of the testis. (1979) (53)
A single heteromeric receptor complex is sufficient to mediate biological effects of transforming growth factor-beta ligands. (1994) (52)
Complete laryngotracheoesophageal cleft: management and repair. (1984) (51)
Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level. (1999) (51)
Enhanced purification of Mullerian inhibiting substance by lectin affinity chromatography (1980) (51)
Müllerian inhibiting substance in the diagnosis and management of intersex and gonadal abnormalities. (1993) (51)
Genome-wide enrichment of damaging de novo variants in patients with isolated and complex congenital diaphragmatic hernia (2017) (50)
Delay of testicular differentiation in the B6.YDOM ovotestis demonstrated by immunocytochemical staining for müllerian inhibiting substance. (1991) (50)
Combined antenatal thyrotropin-releasing hormone and low-dose glucocorticoid therapy improves the pulmonary biochemical immaturity in congenital diaphragmatic hernia. (1994) (50)
Intersex genetic anomalies with malignant potential (2006) (50)
Polygenic Causes of Congenital Diaphragmatic Hernia Produce Common Lung Pathologies. (2016) (50)
Ambiguous genitalia. (1994) (49)
Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice. (1981) (48)
Clinical management of intersex abnormalities. (1991) (48)
Male sex determination: current concepts of male sexual differentiation. (1994) (48)
Prenatal vitamin E treatment improves lung growth in fetal rats with congenital diaphragmatic hernia. (1999) (48)
Müllerian inhibiting substance depresses accumulation in vitro of disaturated phosphatidylcholine in fetal rat lung. (1988) (48)
True hermaphroditism: a clinical description and a proposed function for the long arm of the Y chromosome. (1978) (46)
Müllerian Inhibiting Substance Inhibits Branching Morphogenesis and Induces Apoptosis in Fetal Rat Lung. (1997) (46)
Müllerian inhibiting substance production and cleavage is modulated by gonadotropins and steroids. (1991) (46)
Transcriptional regulation of the rat Müllerian inhibiting substance type II receptor in rodent Leydig cells. (1999) (45)
Maturation of the rectoanal response in premature and perinatal infants. (1977) (45)
Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors (2014) (45)
Periductal and matrix glycosaminoglycans in rat Mullerian duct development and regression. (1982) (45)
Changing patterns of fibronectin, laminin, type IV collagen, and a basement membrane proteoglycan during rat Mullerian duct regression. (1984) (45)
Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor–Directed Transgenic Mouse Ovarian Cancers In vivo (2006) (45)
Congenital diaphragmatic hernia interval on chromosome 8p23.1 characterized by genetics and protein interaction networks (2012) (44)
Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants. (1989) (44)
Molecular pathogenesis of congenital diaphragmatic hernia revealed by exome sequencing, developmental data, and bioinformatics (2014) (44)
Early one-stage surgical reconstruction of the extremely high vagina in patients with congenital adrenal hyperplasia. (1994) (44)
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer (2006) (43)
Prevalence and penetrance of ZFPM2 mutations and deletions causing congenital diaphragmatic hernia (2015) (42)
Immunocytochemical localization of Mullerian inhibiting substance in the rough endoplasmic reticulum and Golgi apparatus in Sertoli cells of the neonatal calf testis using a monoclonal antibody. (1984) (42)
An SRY mutation causing human sex reversal resolves a general mechanism of structure-specific DNA recognition: application to the four-way DNA junction. (1995) (42)
Müllerian-Inhibiting Substance Inhibits Rat Leydig Cell Regeneration after Ethylene Dimethanesulphonate Ablation1 (2004) (41)
AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer (2015) (41)
Type IV laryngotracheoesophageal clefts: surgical management for long-term survival. (1996) (40)
Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. (2016) (40)
The critical period for mullerian duct regression in the dog embryo. (1991) (39)
Prenatal glucocorticoids improve pulmonary morphometrics in fetal sheep with congenital diaphragmatic hernia. (1997) (38)
Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers. (2010) (38)
New approaches for high-yield purification of Müllerian inhibiting substance improve its bioactivity. (2002) (37)
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines. (2011) (36)
Involution of the female Mullerian duct of the fetal rat in the organ-culture assay for the detection of Mullerian Inhibiting Substance. (1979) (36)
Embryonic cell death patterns associated with nitrofen-induced congenital diaphragmatic hernia. (1995) (36)
Anti-Mullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation. (2020) (36)
Persistent Mullerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene. (2003) (35)
Prenatal hormonal therapy improves pulmonary morphology in rats with congenital diaphragmatic hernia. (1996) (35)
Cell migration and activated PI3K/AKT-directed elongation in the developing rat Müllerian duct. (2009) (35)
Type IV collagen drives alveolar epithelial–endothelial association and the morphogenetic movements of septation (2016) (34)
Mullerian Inhibiting Substance Promotes Interferon γ-induced Gene Expression and Apoptosis in Breast Cancer Cells* (2003) (34)
Inhibition of Müllerian Inhibiting Substance Secretion by FSH (1978) (34)
Muscle surface pH as a monitor of tissue perfusion and acid-base status. (1971) (34)
Steroid enhancement of Mullerian duct regression. (1982) (34)
Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo. (1992) (33)
Molecular biology of MIS and its receptors. (1996) (33)
Acetylcholinesterase and manometry in the diagnosis of the constipated child. (1986) (33)
Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. (2005) (33)
Obturator bypass graft in radical excision of inguinal neoplasm. (1967) (32)
Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications (2003) (32)
CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis (2016) (32)
Pelvic kidney in infants and children: experience with 16 cases. (1980) (32)
Evaluation of the infant who has ambiguous genitalia, and principles of operative management. (1996) (32)
Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis. (2012) (32)
Toward understanding the developmental anatomy of congenital diaphragmatic hernia. (1996) (31)
Müllerian inhibiting substance is present in testes of dogs with persistent müllerian duct syndrome. (1989) (30)
Focal Müllerian duct retention in male mice with constitutively activated β-catenin expression in the Müllerian duct mesenchyme (2010) (30)
Primary genitourinary tuberculosis: rapid progression and tissue destruction during treatment. (1986) (30)
Fetal and postnatal testis shows immunoprivilege as donor tissue. (1988) (30)
Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo (2001) (30)
Detection of Müllerian inhibiting substance in biological samples by a solid phase sandwich radioimmunoassay. (1986) (30)
Rejection of murine congenic bile ducts: a model for immune-mediated bile duct disease. (1992) (30)
Crossed renal ectopia in children. (1976) (29)
De novo frameshift mutation in COUP‐TFII (NR2F2) in human congenital diaphragmatic hernia (2016) (29)
The p21(RAS) farnesyltransferase alpha subunit in TGF-beta and activin signaling. (1996) (28)
Ectopic class II major histocompatibility antigens in Hirschsprung's disease and neuronal intestinal dysplasia. (1992) (28)
Production of monoclonal antibodies for affinity purification of bovine mullerian inhibiting substance activity. (1984) (28)
c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. (2008) (28)
The Role of Zinc in Miillerian Duct Regression (1982) (28)
Bile duct perforation in a newborn with stenosis of the ampulla of Vater. (1976) (27)
An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance. (2013) (27)
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo. (2002) (27)
Liver transplantation in children: the Boston Center experience in the first 30 months. (1987) (27)
Müllerian inhibiting substance inhibition of a human endometrial carcinoma cell line xenografted in nude mice. (1984) (27)
Single-cell sequencing of neonatal uterus reveals an Misr2+ endometrial progenitor indispensable for fertility (2019) (27)
The inferior epigastric vein as an alternate site for central venous hyperalimentation. (1980) (26)
Developmentally regulated polyadenylation of two discrete messenger ribonucleic acids for müllerian inhibiting substance. (1992) (26)
Update on the analysis of the need for pediatric surgeons in the United States. (1995) (26)
Müllerian inhibiting substance in sex-reversed dogs. (1987) (26)
Recombinant human müllerian inhibiting substance inhibits epidermal growth factor receptor tyrosine kinase. (1989) (25)
Steroidogenic activities in MA-10 Leydig cells are differentially altered by cAMP and Müllerian inhibiting substance (2004) (25)
Systematic analysis of copy number variation associated with congenital diaphragmatic hernia (2018) (25)
Meiosis I Arrest Abnormalities Lead to Severe Oligozoospermia in Meiosis 1 Arresting Protein (M1ap)-Deficient Mice1 (2013) (25)
Mullerian‐inhibiting substance secretion is delayed in XX sex‐reversed dog embryos (1994) (25)
Extraction of Mullerian inhibiting substance from newborn calf testis. (1979) (25)
Towards international standardization of immunoassays for Müllerian inhibiting substance/anti-Müllerian hormone (2018) (24)
Müllerian inhibiting substance blocks epidermal growth factor receptor phosphorylation in fetal rat lung membranes. (1991) (23)
Prenatal hormones alter antioxidant enzymes and lung histology in rats with congenital diaphragmatic hernia. (1997) (23)
Manometry and histochemistry in the diagnosis of Hirschsprung's disease. (1979) (23)
Sertoli cell production of müllerian inhibiting substance in vitro. (1986) (22)
Nitrofen induces a redox-dependent apoptosis associated with increased p38 activity in P19 teratocarcinoma cells. (2005) (21)
Bilateral rotated buttock flaps for vaginal atresia in severely masculinized females with adrenogenital syndrome. (1992) (21)
Management of neonates and children with male pseudohermaphroditism. (1977) (21)
Ambiguous genitalia--etiology, diagnosis, and therapy. (1995) (20)
Increased Secretion of Müllerian Inhibiting Substance after Immunological Blockade of Endogenous Luteinizing Hormone Releasing Hormone in the Rat (1978) (20)
Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo. (1995) (20)
Müllerian inhibiting substance in reproduction and cancer (1992) (20)
Roux-en-Y on-line intussusception to avoid ascending cholangitis in biliary atresia. (1983) (20)
Cryotherapy of subglottic hemangioma. (1984) (20)
Bioassay, purification, cloning, and expression of müllerian inhibiting substance. (1991) (20)
Perspective: reproductive tract development--new discoveries and future directions. (2001) (19)
The effect of fibronectin on cholinergic differentiation of the fetal colon. (1985) (19)
Computer-aided cell colony counting. (1991) (19)
Perspective: Reproductive Tract Development-New Discoveries and Future Directions. (2001) (19)
Congenital adrenal hyperplasia: surgical considerations required to repair a 46,XX patient raised as a boy. (2003) (19)
Mechanism of action of Mullerian inhibiting substance. (1984) (19)
Improved histology for the chick-quail chimera. (1984) (19)
The role of Müllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization. (2003) (18)
Modulation by sphingolipids of calcium signals evoked by epidermal growth factor. (1994) (18)
Müllerian-inhibiting substance type II receptor expression and function in purified rat Leydig cells. (1999) (18)
Can fetal and newborn allografts survive in an immunocompetent host? (1986) (18)
MiR-449a Affects Epithelial Proliferation during the Pseudoglandular and Canalicular Phases of Avian and Mammal Lung Development (2016) (17)
Gastroesophageal reflux and hiatus hernia in children: experience with 70 cases. (1980) (17)
Development of mullerian inhibiting substance as an anti-cancer drug. (1986) (17)
Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells. (2011) (17)
Human Müllerian-Inhibiting Substance Promoter Contains a Functional TFII-I-Binding Initiator1 (2000) (17)
The surgical management of laryngotracheoesophageal cleft with tracheoesophageal fistula and esophageal atresia. (1972) (17)
Induction of WNT inhibitory factor 1 expression by Müllerian inhibiting substance/antiMullerian hormone in the Müllerian duct mesenchyme is linked to Müllerian duct regression. (2014) (16)
Structure of AMH bound to AMHR2 provides insight into a unique signaling pair in the TGF-β family (2021) (16)
Tracheal ligation increases mitogen-activated protein kinase activity and attenuates surfactant protein B mRNA in fetal sheep lungs. (1999) (16)
Müllerian-Inhibiting Substance/Anti-Müllerian Hormone as a Predictor of Preterm Birth in Polycystic Ovary Syndrome (2018) (16)
The diagnosis and treatment of infants with intersex abnormalities. (1987) (15)
Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Women's Health Across the Nation (2020) (15)
Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smad-independent mechanism. (2006) (15)
Fibroblast androgen receptors in patients with genitourinary anomalies. (1984) (15)
Somatic stem cells of the ovary and their relationship to human ovarian cancers (2009) (15)
Subrenal capsule assay to test the viability of parenterally delivered müllerian inhibiting substance. (1984) (14)
Mullerian inhibiting substance promotes interferon gamma-induced gene expression and apoptosis in breast cancer cells. (2003) (14)
Is Mullerian-inhibiting substance a circulating hormone in the chick-quail chimera? (1983) (14)
Single-cell sequencing reveals suppressive transcriptional programs regulated by MIS/AMH in neonatal ovaries (2021) (14)
Cholinergic nerve development in fetal lung. (1978) (14)
Identification of müllerian inhibiting substance specific binding in human cell lines. (1992) (14)
Decreased mitogen activated protein kinase activities in congenital diaphragmatic hernia-associated pulmonary hypoplasia. (2001) (14)
Differentiation of intramural ganglia in the dissociated rectosigmoid of the rat: an organ culture study. (1977) (14)
Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance. (2010) (13)
Cholinergic nerve development of fetal lung in vitro. (1978) (13)
Effect of E. Coli endotoxin on mammalian cell growth and recombinant protein production (1990) (13)
Developmental changes in mullerian inhibiting substance in the cynomolgus monkey, Macaca fascicularis. (1994) (13)
Masculinizing and feminizing syndromes caused by functioning tumors. (1997) (13)
Identification of a receptor for human müllerian inhibiting substance. (1993) (13)
Müllerian inhibiting substance: New perspectives and future directions (1993) (13)
Cyclic adenosine 3',5'-monophosphate modulation of mullerian duct regression. (1984) (13)
Rare and de novo variants in 827 congenital diaphragmatic hernia probands implicate LONP1 as candidate risk gene. (2021) (13)
Evaluation of the newborn with ambiguous genitalia. (1976) (13)
Expression analysis and evolutionary conservation of the mouse germ cell–specific D6Mm5e gene (2006) (12)
The preservation of Mullerian inhibiting substance during long-term freezing of testicular fragments. (1977) (12)
Androgen stimulation of nucleotide pyrophosphatase during mullerian duct regression. (1984) (12)
SRYand architectural gene regulation: the kinetic stability of a bent protein-DNA complex can regulate its transcriptional potency. (2001) (12)
Müllerian inhibiting substance is anterogradely transported and does not attenuate avulsion-induced death of hypoglossal motor neurons (2011) (12)
Salivary gland heterotopia in the lower part of the neck. (1979) (12)
Luteinizing hormone-releasing hormone-induced delay of parturition. (1980) (12)
Müllerian inhibiting substance inhibits an ovarian cancer cell line via β-catenin interacting protein deregulation of the Wnt signal pathway. (2017) (12)
Development of a sexually differentiated behavior and its underlying CNS arousal functions. (2007) (12)
mechanisms of disease Sex Determination and Differentiation (2004) (12)
Transcriptome analysis reveals that Müllerian inhibiting substance regulates signaling pathways that contribute to endometrial carcinogenesis (2015) (12)
Advances in management of laryngeal and subglottic stenosis. (1982) (11)
Sexual dimorphism of g‐protein subunit Gng13 expression in the cortical region of the developing mouse ovary (2007) (11)
Neoseminal vesicle created from retained mullerian duct to preserve the vas in male infants. (1988) (11)
Regression of the Müllerian ducts during sexual differentiation in the chick embryo. A reappraisal. (1983) (11)
Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics (Proceedings of the National Academy of Sciences of the United States of America (2008) 105, 34, (12469-12473) DOI: 10.1073/pnas.0805012105) (2008) (11)
Mullerian-Inhibiting Substance Induces Gro-β Expression in Breast Cancer Cells through a Nuclear Factor-κB–Dependent and Smad1-Dependent Mechanism (2007) (11)
Liver regeneration during immunosuppression. (1987) (10)
Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer. (2012) (10)
The role of nucleotide pyrophosphatase in Mullerian duct regression. (1983) (10)
Transfection of the mullerian inhibiting substance gene inhibits local and metastatic tumor-growth. (1993) (10)
Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung. (1997) (10)
Distribution of ERK1/2 and ERK3 during normal rat fetal lung development (2006) (9)
Mullerian inhibiting substance binding and uptake (1992) (9)
A possible purification of mullerian inhibiting substance and a model for its mechanism of action. (1985) (9)
Complications of pediatric percutaneous renal procedures: incidence and observations. (1983) (9)
Complications of vaginal atresia in association with a duplicated mullerian duct. (1987) (9)
Aberrant colonic expression of MHC class II antigens in Hirschsprung's disease. (1991) (9)
Follicular fluid anti-Müllerian hormone (AMH) concentrations and outcomes of in vitro fertilization cycles with fresh embryo transfer among women at a fertility center (2020) (8)
Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism. (2007) (8)
Neoadjuvant Treatment With Müllerian-Inhibiting Substance Synchronizes Follicles and Enhances Superovulation Yield (2019) (8)
Müllerian inhibiting substance/anti-Müllerian hormone as a fertility preservation agent (2018) (8)
Mutational Analysis of the Putative Anti-Müllerian Hormone (AMH) Binding Interface on its Type II Receptor, AMHR2 (2020) (8)
The fate of the grafted quail Mullerian duct in the chick embryonic coelom. (1984) (7)
The mandate for innovation in pediatric surgery; creating the environment for success, parity, and excellence. (2008) (7)
Gonadotropins moderate rejection of trophic-specific congenic testes grafts. (1991) (7)
Accurate method to study static volume-pressure relationships in small fetal and neonatal animals. (1994) (7)
Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive. (1996) (6)
Liver transplantation in pediatric patients. (1985) (6)
Müllerian-Inhibiting Substance: Critical Roles in Sexual Differentiation (1994) (6)
Aspergillus-induced small bowel obstruction in a leukemic newborn. (1977) (6)
The infant with ambiguous genitalia. (1997) (6)
Sex differentiation in mouse and man and subsequent development of the female reproductive organs (2010) (6)
Retinoic acid-mediated differentiation protects against nitrofen-induced apoptosis. (2007) (6)
The hormonal control of testicular descent. (1986) (6)
Genetic analysis of de novo variants reveals sex differences in complex and isolated congenital diaphragmatic hernia and indicates MYRF as a candidate gene (2017) (5)
Imperforate anus with long but apparent low fistula in females. (1988) (5)
Zinc chelation and mullerian duct regression. (1984) (5)
Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. (2016) (5)
Mullerian Inhibiting Substance: A Potential Nontoxic, Naturally Occurring Therapeutic Agent for Certain Human Cancers (2008) (5)
Urinary phthalate metabolite concentrations are negatively associated with follicular fluid anti-müllerian hormone concentrations in women undergoing fertility treatment (2020) (4)
Mullerian inhibiting substance: a fetal hormone with surgical implications. (1985) (4)
Mullerian inhibiting substance in the ovary. (1988) (4)
Mullerian inhibiting substance: an update. (1982) (4)
Quantification of Müllerian Inhibiting Substance/Anti-Müllerian Hormone polypeptide by isotope dilution mass spectrometry. (2018) (3)
Prenatal hormonal therapy for lung hypoplasia associated with congenital diaphragmatic hernia (1996) (3)
Genomic structure and expression analysis of the mouse testis-specific ribbon protein (Trib) gene. (2004) (3)
The role of zinc in Müllerian duct regression. (1982) (3)
The Biochemistry And Biology Of Müllerian Inhibiting Substance (1981) (3)
Genetic tools and algorithms for gene discovery in major congenital anomalies. (2009) (2)
Measurements of Serum Mullerian Inhibiting Substance in the Evaluation of Children With Nonpalpable Gonads (1997) (2)
A screen of repurposed drugs identifies AMHR2/MISR2 agonists as potential contraceptives (2022) (2)
Missense variants affecting the actin-binding domains of PLS3 cause X-linked congenital diaphragmatic hernia and body wall defects (2021) (2)
A pediatric surgeon retools in genetics and genomics to study congenital diaphragmatic hernia. (2009) (2)
Subrenal Capsule Assay to Test the Viability of Parenterally Delivered Müllerian Inhibiting Substance (1985) (2)
Single-Stage Surgical Reconstruction for Infants With Congenital Adrenal Hyperplasia (2003) (2)
Genome-wide enrichment of damaging de novo variants in patients with isolated and complex congenital diaphragmatic hernia (2017) (2)
Monoclonal antibodies as physiologic probes. (1983) (2)
Cancer Stem/Progenitor Cells Respond Poorly to Chemotherapeutic Agents (2012) (2)
Erratum to: Type IV collagen drives alveolar epithelial–endothelial association and the morphogenetic movements of septation (2016) (1)
Mullerian Mesenchyme-Specific Activation of Wnt/Beta-Catenin Signaling Inhibits Mullerian Duct Regression and Contributes to Male Infertility. (2010) (1)
Control of Müllerian Inhibiting Substance (1981) (1)
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-2004. A 23-day-old infant with hypospadias and failure to thrive. (2004) (1)
Genomic approaches to surgical diseases: 21st annual Samuel Jason Mixter lecture. (2006) (1)
Findings from aCGH in patients with congenital diaphragmatic hernia (CDH): A possible locus for Fryns syndrome (Am J Med Genet 140A:17–23, 2006) (2006) (1)
Human recombinant mullerian inhibiting substance inhibits epidermal growth factor. (1988) (1)
Gonadotropin Control of Müllerian-Inhibiting Substance (1979) (1)
EXPRESSION OF MULLERIAN INHIBITING SUBSTANCE AND ITS RECEPTOR IN THE HUMAN OVARY (2004) (1)
Abstract AS25: An adeno-associated virus (AAV) 9 vector delivering modified human mullerian inhibiting substance (MIS) as a gene therapy for ovarian cancer (2015) (1)
Monoclonal antibody to Mullerian inhibiting substance. (1982) (1)
Surgical reconstruction of intersex abnormalities (2006) (1)
Chapter 123 – Disorders of Sexual Development (2012) (1)
se 1 modulates transforming ig in the regulation (2016) (0)
Müllerian inhibiting substance as a model for the transforming growth factor-beta family: development of new treatment strategies. (1996) (0)
Book ReviewBefore We Are Born: Basic embryology and birth defects. (1974) (0)
Monoclonal antibody to mullerian inhibiting substance. Abstr. (1981) (0)
Author response: Single-cell sequencing of neonatal uterus reveals an Misr2+ endometrial progenitor indispensable for fertility (2019) (0)
FOLLICULAR FLUID CONCENTRATIONS OF ANTI-MÜLLERIAN HORMONE IN RELATION TO ART OUTCOMES (2020) (0)
Pathogenesis and Treatment of Disorders of Sexual Development (2018) (0)
Figure 4, Identification and functional characterization of label retaining cells in the ovarian surface epithelium. (2009) (0)
MULLERIAN INHIBITING SUBSTANCE (MIS) DETERMINATION IN THE EVALUATION OF NONPALPABLE GONADS. • 534 (1996) (0)
Resarch in Clinical Care in Pediatric Surgery(the 44th Annual Meeting of Japanese Society of Pediatric Surgeons) (2007) (0)
Abstract B26: Cell surface expression of CD44v8-10 is associated with good prognosis while cleaved extracellular domain is a marker of poor prognosis in high-grade serous epithelial ovarian cancer. (2016) (0)
Rejecti Model .on of Murine Congenic Bile Ducts: A for Immune-Mediated Bile Duct Disease (1992) (0)
Mullerian Inhibiting Substance: Studies on its Mechanism of Action and Activity as an Anti-Tumor Agent (1989) (0)
Findings in LRP2 mutation positive versus LRP2 mutation negative cases referred for DBS (2008) (0)
Abstract AP29: A SINGLE CELL RNA-SEQUENCING APPROACH TO UNCOVERING HUMAN OVARIAN TUMOR AND IMMUNE CELL HETEROGENEITY, AND THEIR RESPONSE TO MULLERIAN INHIBITING SUBSTANCE USING PATIENT ASCITES SAMPLES (2019) (0)
PROGRAMMED CELL DEATH IN THE MUELLERIAN DUCT INDUCED BY MUELLERIAN INHIBITING SUBSTANCE. (1977) (0)
List of Contributors and Discussants (1981) (0)
Anti-müllerian hormone (AMH) induces aromatase expression in human granulosa cells (2008) (0)
MULLERIAN INHIBITING SUBSTANCE (MIS) IN THE EVALUATION OF CHILDREN WITH NONPALPABLE GONADS (1993) (0)
Figure 3, Intraovarian transplantation of the thecal stem cells. (2009) (0)
Engineered tissue using transfected cells inhibits tumor growth (2001) (0)
TREATING HUMAN OVARIAN CANCER CELLS (2017) (0)
SCL17 Mullerian Inhibiting Substance as a treatment strategy for ovarian cancer and other reproductive cancers (2000) (0)
Mullerian-inhibiting substance as a cancer therapeutic agent (1985) (0)
Monoclonal antibody specific for mullerian inhibiting substance. Abstr. (1983) (0)
The Endocrine Society 2004 annual awards. (2004) (0)
Identification and characterization of genetic hotspots and potential candidate genes for congenital diaphragmatic hernia by high density array comparative genomic hybridization (2008) (0)
Patents And literature (1985) (0)
(Mullerian inhibiting substance/P450 aromatase/transcription factors/DNA-binding proteins/sexual dimorphism) (2016) (0)
Type IV collagen drives alveolar epithelial–endothelial association and the morphogenetic movements of septation (2016) (0)
THEREOF FORTREATMENT OF CANCER AND EXCESS ANDROGEN STATES (2017) (0)
Human Miillerian Inhibiting Substance Inhibits Tumor Growth in Vitro and in Vivo1 (2006) (0)
Single-cell sequencing of neonatal uterus reveals an endometrial progenitor indispensable for fertility (2019) (0)
Elevated anti-mullerian hormone as a predictor of spontaneous preterm delivery for women with polycystic ovary syndrome (2018) (0)
Mullerian-inhibiting substanc signaling in the prostate in i (2016) (0)
P599: Trends in prenatal genetic diagnosis for congenital diaphragmatic hernia: A 20-year single center retrospective review (2023) (0)
Figure 6, Isolation and characterization of candidate human ovarian tumor cancer initiating cells form self-renewing, anchorage-independent spheroids under stem cell–selective conditions. (2009) (0)
Purification d'hormone antimullerienne (1992) (0)
Patents and literature (1985) (0)
Survival of fetal and neonatal testis congenic grafts correlates with reduced major histocompatibility complex burden (1988) (0)
Müllerian Inhibiting Substance: New Insights (2004) (0)
Preputial Unfurling to Correct the Buried Penis (1987) (0)
Complications of Vaginal Atresia in Association with a Duplicated Mullerian Duct (1988) (0)
Mullerian Inhibiting Substance (MIS) Levels in Children with Ovarian Tumors† 447 (1998) (0)
WS4-1 "High vaginal pull through procedures for Congenital Adrenal Hyperplasia and cloacal deformities" (2000) (0)
Treatment of Male Infertility (1982) (0)
Chapter 121 – Ambiguous Genitalia (2006) (0)
Stainless steel mesh supports high density cell growth and production of recombinant Mullerian Inhibiting Substances (1989) (0)
Erratum to: Type IV collagen drives alveolar epithelial–endothelial association and the morphogenetic movements of septation (2016) (0)
Molecular Mechanisms of Mullerian Inhibiting Substance-Mediated Apoptosis (1997) (0)
Abstract 1779: Anti-Müllerian hormone type II receptor (AMHRII), a cancer target for GM103, a novel antibody-drug conjugate (ADC) (2018) (0)
MIS induces the cell cycle inhibitor p27, alters Rb/ E2F family proteins, and causes apoptosis and growth arrest of breast cancer cells (2000) (0)
Follicular fluid (FF) concentration of anti-müllerian hormone (AMH) in women pursuing in vitro fertilization (IVF): variability and predictors (2019) (0)
Sustained inquiry: in the clinic and at the bench. (2004) (0)
HIGHER LEVELS OF MATERNAL SERUM ANTI-MULLERIAN HORMONE ARE ASSOCIATED WITH AN INCREASED MALE-TO-FEMALE NEONATE RATIO AFTER IVF/ICSI (2020) (0)
Abstract A63: Whole-genome CRISPR/CAS9 screen using patient samples reveals JunB as a unique genetic liability (2020) (0)
Figure 3, A schematic model of MIS actions at the early stage of Müllerian duct regression. (2010) (0)
Surgical treatment of disorders of sexual development (2013) (0)
Figure 5, Characterization of MOVCAR 7 side population cells. (2009) (0)
Figure 2, [A three phase model for...]. (2010) (0)
herniahistology in rats with congenital diaphragmatic Prenatal hormones alter antioxidant enzymes and (2012) (0)
Rare and de novo variants in 827 congenital diaphragmatic hernia probands implicate LONP1 and ALYREF as new candidate risk genes (2021) (0)
Engineered tissue using transfected cells inhibits tumor growth (for surgical oncology category) (2000) (0)
Figure 1, [Formation, proliferation, and migration of mouse primordial germ cells]. (2010) (0)
Endometrial cancer expresses the Mullerian Inhibiting Substance (MIS) type II receptor and is growth inhibited by MIS (2004) (0)
Mullerian-inhibiting substance augments ovarian response to superovulation in mice with diminished ovarian reserve (2018) (0)
Title Type IV collagen drives alveolar epithelial-endothelial association and the morphogenetic movements of septation Permalink (2016) (0)
FOXP1 Haploinsufficiency Contributes to the Development of Congenital Diaphragmatic Hernia (2021) (0)
Figure 2, Schematic representation of ovarian embryonic development. (2009) (0)
Mullerian Inhibiting Substance Activity in the Development of the Reproductive Tract and Lung in the Fetus and Control of Oocyte Meiosis in the Adult (1991) (0)
Figure 1, Schematic summary of current evidence for ovarian somatic stem cells. (2009) (0)
THE CONTIBUTIONS OF JAPANESE SURGEONS TO THE UNDERSTANDING OF MULLERIAN INHIBITING SUBSTANCE, ITS ROLE IN INTERSEX ABNORMALITIES AND ITS DEVELOPMENT AS AN ANTITUMOR AGENT (1985) (0)
Mullerian Inhibiting Substance Inhibits the Growth of Ocular and Metastatic Uveal Melanoma Cells (2007) (0)
Mullerian Inhibiting Substance Gene Expression in the Cycling Rat Ovary Correlates with Recruited or Graafian Follicle Selection 1 (2004) (0)

This paper list is powered by the following services:

Other Resources About Patricia K. Donahoe

en.wikipedia.org

What Schools Are Affiliated With Patricia K. Donahoe?

Patricia K. Donahoe is affiliated with the following schools:

Patricia K. Donahoe's Academic­Influence.com Rankings